2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18965R
    TAS-301 (Standard) 193620-69-8
    TAS-301 (Standard) is the analytical standard of TAS-301. This product is intended for research and analytical applications. TAS-301 is an inhibitor of smooth muscle cell migration and proliferation, and inhibits PKC activation induced by PDGF.
    TAS-301 (Standard)
  • HY-19026R
    Siguazodan (Standard) 115344-47-3 98%
    Siguazodan (Standard) is the analytical standard of Siguazodan. This product is intended for research and analytical applications. Siguazodan (SKF 94836) is a potent, selective and orally active phosphodiesterase III (PDE-III) inhibitor with an IC50 of 117 nM. Siguazodan increases cAMP accumulation in intact platelets with an EC50 of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC50 value of 4.2 μM.
    Siguazodan (Standard)
  • HY-19219A
    BMS-189664 hydrochloride 185252-36-2 98%
    BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research.
    BMS-189664 hydrochloride
  • HY-19321R
    PF-06282999 (Standard) 1435467-37-0
    PF-06282999 (Standard) is the analytical standard of PF-06282999. This product is intended for research and analytical applications. PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.
    PF-06282999 (Standard)
  • HY-19399A
    (±)-Iroxanadine 203805-20-3 98%
    (±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research.
    (±)-Iroxanadine
  • HY-19399C
    Iroxanadine hydrobromide 276690-62-1 98%
    Iroxanadine hydrobromide (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrobromide has the potential for atherosclerosis and vascular diseases research.
    Iroxanadine hydrobromide
  • HY-19399D
    Iroxanadine hydrochloride 276690-59-6 98%
    Iroxanadine (BRX 005) hydrochloride is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrochloride has the potential for atherosclerosis and vascular diseases research.
    Iroxanadine hydrochloride
  • HY-19664R
    Pranidipine (Standard) 99522-79-9 98%
    Pranidipine (Standard) is the analytical standard of Pranidipine. This product is intended for research and analytical applications. Pranidipine (OPC-13340) is a potent, long acting 1,4-dihydropyridine calcium channel blocker with antihypertensive activity.
    Pranidipine (Standard)
  • HY-19666R
    DPI 201-106 (Standard) 97730-95-5 98%
    DPI 201-106 (Standard) is the analytical standard of DPI 201-106. This product is intended for research and analytical applications. DPI 201-106 (SDZ 201106) is a cardiotonic agent with a synergistic sarcolemmal and intracellular mechanism of action. DPI 201-106 shows cardioselective modulation of voltage-gated sodium channels (VGSCs) resulting in a positive inotropic effect.
    DPI 201-106 (Standard)
  • HY-19693R
    Cariporide (Standard) 159138-80-4 98%
    Cariporide (Standard) is the analytical standard of Cariporide. This product is intended for research and analytical applications. Cariporide (HOE-642) is a selective Na+/H+ exchange inhibitor.
    Cariporide (Standard)
  • HY-40294R
    Indazole (Standard) 271-44-3
    Indazole (Standard) is the analytical standard of Indazole. This product is intended for research and analytical applications. Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
    Indazole (Standard)
  • HY-42680R
    D-Tagatose (Standard) 87-81-0 98%
    D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose (Standard)
  • HY-43670R
    Chlorthalidone impurity (Standard) 5270-74-6
    Chlorthalidone impurity (Standard) is the analytical standard of Chlorthalidone impurity. This product is intended for research and analytical applications. Chlorthalidone impurity is a metabolite of Chlorthalidone (HY-15833). Chlorthalidone is a thiazide-like diuretic used to treat hypertension.
    Chlorthalidone impurity (Standard)
  • HY-50291R
    HOKU-81 (Standard) 58020-43-2 98%
    HOKU-81 (Standard) is the analytical standard of HOKU-81. This product is intended for research and analytical applications. HOKU-81 (4-Hydroxytulobuterol) is one of the metabolites of Tulobuterol (HY-B1810). HOKU-81 is a potent and selective β2-adrenoceptor stimulant. HOKU-81 has bronchodilating effect.
    HOKU-81 (Standard)
  • HY-50722B
    NNC 55-0396 free base 357400-14-7 98%
    NNC 55-0396 free base is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396 free base
  • HY-70037R
    Cinacalcet (Standard) 226256-56-0 98%
    Cinacalcet (Standard) is the analytical standard of Cinacalcet. This product is intended for research and analytical applications. Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease research.
    Cinacalcet (Standard)
  • HY-76520S
    Sitaxsentan-13C6 98%
    Sitaxsentan-13C6 (IPI 1040-13C6) is 13C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.
    Sitaxsentan-13C6
  • HY-76948R
    5-R-Rivaroxaban (Standard) 865479-71-6 98%
    5-R-Rivaroxaban (Standard) is the analytical standard of 5-R-Rivaroxaban. This product is intended for research and analytical applications. 5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban (Standard)
  • HY-77521R
    Dabigatran (ethyl ester hydrochloride) (Standard) 211914-50-0 98%
    Dabigatran ethyl ester hydrochloride (Standard) is the analytical standard of Dabigatran ethyl ester hydrochloride (HY-77521). This product is intended for research and analytical applications. Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor.
    Dabigatran (ethyl ester hydrochloride) (Standard)
  • HY-79593R
    MRE-269 (Standard) 475085-57-5 98%
    MRE-269 (Standard) is the analytical standard of MRE-269. This product is intended for research and analytical applications. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
    MRE-269 (Standard)
Cat. No. Product Name / Synonyms Application Reactivity